1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Beijing Tong Ren Tang Chinese Medicine Company Limited

Beijing Tong Ren Tang Chinese Medicine Company Limited

3613.HK
Beijing Tong Ren Tang Chinese Medicine Company LimitedHK flagHong Kong Stock Exchange
6.57
HKD
- -
- -
5.50BMarket Cap
Beijing Tong Ren Tang Chinese Medicine Company Limited
3613.HK
(Hong Kong Stock Exchange)

Recent

price

6.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.4
0.82
0.92
1.16
1.3
1.51
1.81
1.71
1.57
1.86
2.07
1.82
1.93
1.81
1.67
Revenue per Share
- -
0.19
0.29
0.35
0.42
0.5
0.59
0.69
0.66
0.65
0.73
0.77
0.65
0.6
0.47
0.65
Basic EPS, GAAP
- -
0.14
0.02
0.21
0.39
0.51
0.52
0.63
0.64
0.12
0.9
0.61
0.52
-0.31
0.94
- -
Free Cash Flow per Basic Share
- -
- -
0.13
0.08
0.1
0.13
0.16
0.19
0.95
0.23
0.24
0.53
0.33
0.33
0.35
- -
Dividend per Share
- -
0.59
1.1
1.8
2.2
2.57
2.99
3.49
3.21
3.63
4.11
4.35
4.67
4.94
5.06
3.17
Book Value per Share
- -
0.68
1.75
1.85
2.21
2.56
3.02
3.53
3.23
3.67
4.16
4.4
4.74
4.99
5.14
3.19
Tangible Book Value per Share
- -
830
749
830
836
837
837
837
837
837
837
837
837
837
837
837
Basic Weighted Avg Shares
- -
333
614
761
970
1,084
1,266
1,514
1,433
1,315
1,556
1,731
1,525
1,612
1,513
1,402
Sales/Revenue/Turnover
- -
33.71
40.79
44.94
46.25
48.29
47.05
46.04
45.35
51
50.32
47.1
41.89
35.61
35.39
46.92
Operating Margin (%)
- -
11
15
18
23
24
27
31
79
78
70
75
83
88
98
- -
Depreciation Expense
- -
156
220
287
354
420
490
581
556
542
608
646
540
500
397
540
Net Income, GAAP
- -
21.53
16.18
17.04
17.97
17.36
17.26
16.59
16.3
17.21
16.3
16.3
14.13
15.97
17.4
17.16
Effective Tax Rate (%)
- -
46.82
35.83
37.73
36.5
38.76
38.7
38.36
38.82
41.24
39.06
37.31
35.44
31.04
26.25
38.53
Profit Margin (%)
194
416
1,062
1,229
1,541
1,834
2,207
2,606
2,337
2,716
3,064
3,264
3,514
3,730
3,858
2,316
Working Capital
- -
- -
- -
- -
1
1
1
1
60
65
75
61
75
66
74
1
LT Debt
410
568
1,310
1,537
1,909
2,227
2,608
3,024
2,766
3,130
3,540
3,739
4,021
4,246
4,369
2,748
Total Equity
- -
17.64
21.94
19.61
21.03
20.57
20.1
20.44
18.02
17.77
18.86
17.84
13.54
11.36
10.09
20.71
Return on Invested Capital (%)
- -
36.59
29.77
23.19
19.19
19.15
19.47
19.77
18.15
16.94
16.35
15.95
12.26
11.06
8.52
20.26
Return on Capital (%)
- -
44.93
33.37
24.71
21.24
21.08
21.06
21.39
19.82
18.96
18.76
18.22
14.31
12.44
9.49
21.94
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
- -
- -
- -
LT Borrowings
1
- -
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
837
- -
837
Market Capitalization
8,890
12,339
13,461

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
2,355
- -
2,526
Cash, Cash Equivalents & STI
1,898
- -
1,971
Accounts Receivable, Net
171
- -
216
Inventories
236
- -
289
Total Current Liabilities
147
- -
210
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.91%
6.95%
2.88%
Free Cash Flow
-0.33%
4.45%
-402.72%
Net Income, GAAP
2.1%
-5.21%
-20.6%
Sales/Revenue/Turnover
5.17%
3.45%
-6.1%
Total Cash Common Dividend
- -
- -
6.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,525
2024
- -
- -
- -
- -
1,612
2025
- -
- -
- -
- -
1,513

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.65
2024
- -
- -
- -
- -
0.6
2025
- -
- -
- -
- -
0.47

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.33
2024
- -
- -
- -
- -
0.33
2025
- -
- -
- -
- -
0.35
Similar Companies
H. Lundbeck A/S (HLUBF)
Unity Biotechnology, Inc. (0YC0.L)
Ipsen S.A. (IPN.PA)
Hisamitsu Pharmaceutical Co., Inc. (HTSUY)
Global Roundtable Corporation (GRCU)
Neuphoria Therapeutics Inc. (NEUP)
Business
Beijing Tong Ren Tang Chinese Medicine Company Limited engages in the manufacture, retail and wholesale of traditional Chinese medicines and healthcare products, as well as the provision of Chinese medical consultation and treatment services; it operates through three segments including Hong Kong, Mainland China and overseas markets spanning Asia, Oceania, North America, Europe and other regions. The company offers a comprehensive portfolio exceeding 1,000 varieties of proprietary Chinese medicines such as Angong Niuhuang Pills, Jin Chai Shi Hu San, Rhodiola Rosea Capsule, Blueberry & Rhodiola Rosea Capsule, Sporoderm-Broken Ganoderma Lucidum Spores Powder and Lingzhi Turmeric Compound Blood-supplementing and Nerve-calming Capsules; healthcare supplements including herbal teas, coffees and natural health products; deer-based products like deer velvet, deer tail, deer pizzle, deer sinew, deer blood and deer placenta; and services encompassing TCM diagnosis, acupuncture, moxibustion, cupping therapy, Tui Na massage and herbal dispensary operations under the Tong Ren Tang brand. Founded in 1669 during the Qing Dynasty and designated as the imperial pharmacy from 1723, the company maintains its headquarters in Wan Chai, Hong Kong, with production facilities including a GMP- and ISO22000-certified base in Tai Po; it functions as a subsidiary of Tong Ren Tang Technologies Co. Ltd, which is ultimately controlled by China Beijing Tong Ren Tang Group Co., Ltd. In recent developments, the company entered a strategic cooperation agreement with China Duty Free International Limited to leverage synergies in TCM culture and global consumer goods distribution; launched deer products in New Zealand combining traditional techniques with local standards; renewed its exclusive distributorship framework with Beijing Tong Ren Tang Company Limited; added a new retail outlet in Yuen Long, Hong Kong, and upgraded existing stores; obtained a Chinese patent for an anti-aging product preparation method and advanced clinical trials for new capsules; and expanded research collaborations with institutions like Hong Kong Baptist University, Macau University of Science and Technology and City University of Macau, while pursuing product registrations and cultural exchanges in Cambodia and the Middle East. For the six months ended June 30, 2025, the company reported revenue of HK$761.7 million, up 14.6% year-over-year, with profit attributable to owners at HK$234.9 million.